论文部分内容阅读
应用放射免疫法测定１５例前列腺癌、６０例前列腺增生、６０例慢性前列腺炎以及４０例非前列腺疾病患者的血清ＰＳＡ值，并随访观察８例前列腺癌患者接受内分泌治疗后ＰＳＡ值变化。结果表明，前列腺癌的ＰＳＡ阳性率明显高于其它疾病组（Ｐ＜０．０１），其敏感性为９３．３％；特异性不高，为７４．４％，作为前列腺癌的筛选指标有一定的局限性。但对前列腺癌的分期、疗效监测有较大价值，其数值升高或下降与临床症状和体征变化呈正相关关系。
Serum PSA was measured by radioimmunoassay in 15 cases of prostate cancer, 60 cases of benign prostatic hyperplasia, 60 cases of chronic prostatitis and 40 cases of non-prostatic diseases. The PSA values of 8 patients with prostate cancer after follow-up were observed. The results showed that the positive rate of PSA in prostate cancer was significantly higher than that in other diseases (P <0.01), with a sensitivity of 93.3% and a low specificity of 74.4%. As a screening index for prostate cancer Some limitations. However, the staging of prostate cancer, efficacy monitoring has great value, the value of the increase or decrease and clinical symptoms and signs of change was positively correlated.